Non-Hodgkin Lymphoma Treatment Plan

Chemoimmunotherapy cures many lymphomas; focal residual disease is ablated locally.

Treatment

Non-Hodgkin Lymphoma

Staging before the plan

Core/excision biopsy with immunophenotyping, PET-CT and marrow assessment define subtype and stage.

Treatment modalities we may use

  • 01R-CHOP and subtype-specific chemoimmunotherapy
  • 02Targeted agents and CAR-T for relapsed disease
  • 03Ablation of a PET-positive residual mass
  • 04Embolization of rare bulky vascular disease

How the pathway is sequenced

Systemic therapy leads; end-of-treatment PET decides whether a residual site is scar or active disease — a solitary active residual can be ablated or irradiated, sparing patients further systemic chemotherapy.

At Guangzhou St. Stamford Hospital every pathway is decided by a multidisciplinary tumour board: interventional radiologists, medical oncologists, surgeons and imaging specialists review your actual scans together. Send us your imaging and pathology before you travel and receive a written, stage-specific treatment plan in English.

Still have questions?

Reach our care team for personalized guidance on diagnosis, treatment, and insurance.

Request a Consultation
← Back to Treatment